Multicenter, USA - 04 Apr `17Incyte: A Study of Ruxolitinib 1,5% cream

Official Title: A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo

In Brief: The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.

Description: Ruxolitinib cream 1.5% twice-daily for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension

Details: Check Incyte announcement or download pdf with a scientific presentation from UMass.

Ages Eligible: 18 Years to 75 Years

Start Date: April 19, 2017

Completion Date (estimated): September 2021

Status: Active, not recruiting

Study ID from ClinicalTrials.gov: NCT03099304
Other Study ID Numbers: INCB 18424-211 

Location: 26 locations across the United States

Contact: To learn more about this study, you or your doctor may contact Incyte Corporation Call Center by phone +800 00027423 or email globalmedinfo@incyte.com. Please refer to this study by its NCT number.

FAQOther Questions

  • Can Ginkgo Biloba help with vitiligo?

    Ginkgo Biloba seems to be a simple, safe, inexpensive and fairly effective therapy for vitiligo. It is mostly effective in halting the progression of the disease. It can also sp...

  • Are there any famous people with vitiligo?

    Many celebrities have dealt with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career. Here are a few courageous famous peo...

  • Will it spread?

    Vitiligo activity may vary considerably from person to person. In a good number of patients the disease goes on for 3-4 years and then it settles down, with one or two stubborn...